Across TCGA pan-cancer cohorts, LINC02622 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02622’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02622 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02622 is over-expressed in tumor.
BRCA are the cancer types where LINC02622 tumor–normal differential expression is most reproducible.